Modina (Nimodipine)

Nimodipine acts on the cerebrovascular system to prevent arterial narrowing after hemorrhagic events.

• Subarachnoid hemorrhage: Reduces the incidence of cerebral vasospasm and associated ischemic complications.
• Cerebral vasospasm: Prevents narrowing of cerebral arteries following subarachnoid hemorrhage, supporting sustained cerebral perfusion.

• Nimodipine antagonizes L-type calcium channels on vascular smooth muscle, especially in cerebral arteries. This inhibition leads to vasodilation of intracranial vessels, increasing cerebral blood flow and mitigating the development of vasospasm after subarachnoid hemorrhage.

Nimodipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: transient warmth and redness.
• Nausea: occasional upset stomach.
• Dizziness: especially on standing.
• Hypotension: mild blood pressure reduction.
• Peripheral edema: mild swelling of ankles.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Cardiac arrhythmias: irregular heart rhythms.
• Hepatotoxicity: abnormal liver function tests.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Seizures: rare neurologic events.
• Myocardial infarction: very rare cardiac event.

Before prescribing Nimodipine, clinicians should evaluate patient-specific factors and monitor for potential complications.

• Cardiovascular disease: assess baseline blood pressure and cardiac status.
• Hepatic impairment: consider dose adjustment or increased monitoring.
• Renal impairment: monitor renal function, especially in severe cases.
• Concomitant vasodilators: avoid additive hypotensive effects.
• Pregnancy and lactation: use only if clearly needed; safety data are limited.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Nimodipine can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nimodipine plasma levels and risk of toxicity.
• Concurrent use with other potent vasodilators: can cause severe hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Beta‑blockers: may enhance bradycardia.
• Diuretics: may potentiate blood‑pressure lowering.
• Antihypertensive agents: monitor for additive effects.